Skip to main content
47°
Light Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lantheus Holdings
(NQ:
LNTH
)
60.46
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lantheus Holdings
< Previous
1
2
Next >
Lantheus to Present at the Leerink Partners Global Biopharma Conference 2024
March 05, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces the FDA Approval of DEFINITY® (Perflutren Lipid Microsphere) for Pediatric Patients
March 04, 2024
DEFINITY is the #1 utilized ultrasound enhancing agent in the U.S. for patients with suboptimal echocardiograms
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Promotion of Amanda Morgan to Chief Commercial Officer
February 28, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
February 13, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
February 08, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces CEO Succession Plan
January 23, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
January 11, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
January 09, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
January 09, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the Jefferies London Healthcare Conference
November 08, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Third Quarter 2023 Financial Results
November 02, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a.m. Eastern Time
October 19, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting
September 01, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the Wells Fargo Healthcare Conference
August 31, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Agreement to Sell RELISTOR® Royalties to HealthCare Royalty
August 03, 2023
Agreement enhances Lantheus’ strong liquidity position and supports continued pipeline advancement and commercial readiness
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports Second Quarter 2023 Financial Results
August 03, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Host Second Quarter 2023 Earnings Conference Call and Webcast on August 3, 2023, at 8:00 a.m. Eastern Time
July 20, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting
June 12, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Payment to Contingent Value Rights (CVR) Holders of $99.7 million or $1.15 per CVR
May 23, 2023
PYLARIFY success leads to maximum payment in first year
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Reports First Quarter 2023 Financial Results
May 04, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation for ¹⁷⁷Lu-PNT2002 for the Treatment of Metastatic Castration Resistant Prostate Cancer
April 24, 2023
From
Lantheus Holdings, Inc.; POINT Biopharma Global Inc.
Via
GlobeNewswire
Lantheus to Host First Quarter 2023 Earnings Conference Call and Webcast on May 4, 2023, at 8:00 a.m. Eastern Time
April 20, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Announces Two Key Executive Promotions
March 17, 2023
Paul Blanchfield promoted to President; Dan Niedzwiecki promoted to Chief Administrative Officer
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Are These Medical Device Makers Getting Ready To Rally?
March 10, 2023
Current trends and changing demographics are behind growth of medical technology companies. An aging population and a shift to in-home care are among factors.
Via
MarketBeat
Lantheus Reports Fourth Quarter and Full Year 2022 Financial Results
February 23, 2023
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
Lantheus Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels
February 16, 2023
Data presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium Demonstrate Potential Benefits of Piflufolastat F 18 Decision Making on Treatment Plans
From
Lantheus Holdings, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.